Allogene Therapeutics Inc R&D Showcase Transcript
It's so great to see so many of you in the room in person. It has been long overdue. Welcome, and thank you for joining us today in our R&D Showcase. As I said, many of you are here in this room, but there are a lot more who are joining us online. My name is David Chang, President and CEO and Co-Founder of Allogene.
Many of us have been immersed in cell therapy and sometimes forget to realize that we are in the early days of creating a new modality that many -- that is unlike any before it. A single infusion that can induce deep and durable responses where we now talk about the possibility of cure, even in the advanced and refractory disease setting.
CD19 CAR T trial had a humble beginning as an investigator-sponsored academic trial in 2019, but quickly gained the momentum as early reports of complete remission were published a few years later. That got the attention of many in biotech, leading to approval of the first autologous CAR T directed therapies at CD19 in 2017, YESCARTA and KYMRIAH.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |